PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets

(2019) Maximilian Stahl et al.   Current Oncology Reports

Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma

(2019) Jing Nie et al.   JOURNAL OF CLINICAL ONCOLOGY

Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges

(2018) Mansour Alfayez et al.   Expert Review of Hematology

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation

(2017) Thomas Schroeder et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

(2016) Matthew S. Davids et al.   NEW ENGLAND JOURNAL OF MEDICINE

A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent

(2014) J J Scarisbrick et al.   BONE MARROW TRANSPLANTATION

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

(2010) Abhinav Deol et al.   CANCER TREATMENT REVIEWS

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH